For what cough is Ascoril used?

Dosage forms, composition

Ascoril is intended for oral administration and is produced in two convenient pharmaceutical forms:

• Tablets: white, uncoated, contain mucolytics guaifenesin, bromhexine and salbutamol as active compounds. For the gradual release of active substances, the drug is supplemented with magnesium stearate, talc, starch and other excipients. In one cardboard package: 1–5 blisters of tablets of 10 pieces.
• Ascoril expectorant syrup: a sweetish, transparent yellow, water-based liquid with the aroma of mint, currants and pineapple. Concentration of active substances in 10 ml of solution: 100 mg. guaifenesin, 2 mg. salbutamol and 4 mg. bromhexine. The composition is supplemented with sorbitol, menthol, citric acid, glycerin and other additives. Ascoril bottles contain 100 and 200 ml of syrup.

Tablets and liquid have a similar mucolytic effect for productive cough.

What cough to take: doctor's advice

The drug in question can be used in the treatment of nonproductive or wet cough. Most often, Ascoril is prescribed for diseases accompanied by a dry cough. This is due to the fact that the composition contains guinesin, which increases and evacuates pulmonary secretions. Ascoril syrup is excellent for the treatment of acute and chronic respiratory diseases, which are characterized by a strong and barking cough.

We recommend that you read about how to treat a barking cough in a child in this material.

This should include:

• Chronical bronchitis;

• pneumonia;
• pulmonary tuberculosis;
• bronchial asthma;
• whooping cough.

How does Ascoril work?

Bromhexin and guaifenesin stimulate the production of the serous component of secretory mucus in the bronchi. Due to this, the volume of sputum increases, it becomes less viscous and thick, and is easier to separate when coughing. Salbutamol reduces the activity of receptors that cause spasm of the walls of the respiratory tract, promotes the expansion of the bronchial lumen, and facilitates breathing.

Ascoril has a complex bronchodilator, mucolytic and antispasmodic effect:

• stimulates the work of epithelial cilia, pushing mucus upward;
• dilutes and facilitates secretion removal;
• increases the productivity of wet cough, promotes the transition of dry to productive;
• increases lung volume;
• reduces the number of convulsive coughing attacks that interfere with the normal discharge of mucus.

The drug does not contain codeine or similar substances that affect specific centers of the brain. It is recommended to use it for diseases accompanied by increased production of mucous secretions. Ascoril does not affect the duration and intensity of pathologies; it acts directly on the area of ​​the lungs and bronchi.

Effect of Ascoril syrup against wet cough

Ascoril is a mucolytic drug that has an expectorant and bronchodilator effect. With its help it is possible to cure very complex diseases.

Read how to take Ascoril cough syrup correctly here.

This drug contains components that allow Ascoril to have such a powerful effect in treating cough:

1. Bromhexine . This component has an antitussive and expectorant effect. Thanks to its presence, it is possible to activate the cilia of the epithelium on the mucous membrane of the trachea and bronchi. In addition, bromhexine dilutes the secretion and promotes its speedy evacuation.
2. Salbutamol. This is a bronchodilator, which is presented in the syrup as sulfate. Affects receptors in blood vessels. Thanks to it, it is possible to prevent and reduce contraction of the bronchi, giving their muscles smoothness and relaxation. The substance in question is involved in the production of endogenous surfactant, which envelops the lungs from the inside, as a result of which the alveoli do not connect, and also takes part in relaxing the muscles of the bronchi.
3. Guaifenesin. This component has an expectorant effect. In addition, it makes sputum less frequent and reduces its surface tension. Thanks to the presence of this component, the bronchi begin to perform more active actions, as a result of which sputum will be evacuated.

What cough is Bromhexine listed here for?

When to use Ascoril: instructions

The solution and the medication in tablets have the same indications:

• symptoms of viral or bacterial pneumonia: deep wheezing in the lungs, difficulty breathing, cough with thick, difficult-to-clear sputum;
• acute or chronic infectious bronchitis;
• obstructive bronchial disease;
• asthmatic damage to the bronchi;
• bronchitis of unknown origin, accompanied by cough and breathing difficulties;
• tracheitis.

Ascoril is ineffective for prolonged dry cough caused by irritation of receptors, not accompanied by the production of mucous secretion.

In what case can treatment begin?

Many mothers are interested in the question of what cough children are given Ascoril for. To answer this, you need to read the instructions for use of the medicine and consult with your doctor.

Ascoril is recommended for use in cases of lung diseases that are accompanied by a wet cough. These include bronchitis and pneumonia. Additionally, they can be taken for diseases such as tracheobronchitis. This remedy is quite effective in treating various complications that can occur against the background of ordinary bronchial asthma and bronchitis obstruction.

Many doctors recommend taking syrup for whooping cough, accompanied by a severe paroxysmal cough.

The syrup also helps well with pulmonary tuberculosis.

Many people know such a disease as cystic fibrosis. This is a disease that is accompanied by pulmonary edema. With this diagnosis, children are also prescribed Ascoril.

Attention! Treatment with the drug should be started carefully and only after a thorough examination. It is very important to know the exact diagnosis of the disease that the patient suffers from.

The medicine is best taken under the strict supervision of a doctor. The pediatrician should regularly examine the baby and identify the characteristics of the pathology. In some children, bronchitis is accompanied by copious amounts of sputum. In this case, Ascoril does not need to be taken. But if we are talking about a dry cough, in which sputum is very difficult to separate and is practically not removed from the body, Ascoril will be very effective.

• Ascoril for dry cough: aspects of use

We can conclude which cough Ascoril syrup will help with. But it is also clear that it is better not to start treating yourself with this remedy. You should definitely consult your doctor first.

Dosage and dosage regimens

It is advisable to buy Ascoril and start treatment from the first days of a wet cough or the appearance of congestion in the lungs. In this case, it will take less time to eliminate symptoms. You need to take the medicine before or after meals.

It is recommended to take the drug in tablets with plain water; carbonated or mineral water is not suitable for this purpose:

• for children from 6 to 12 years old, ½ piece is enough. three times a day - for a mild or moderate cough, 1 pc. three times a day - if the inflammatory process is started;
• Teenagers and adults should take 1 tablet three times a day.

Course of use of Ascoril: 3–5 days. If there is no result of therapy, the drug should be replaced or consult a doctor about extending it.

Ascoril syrup is suitable for the treatment of patients 2 years of age and older for whom swallowing tablets is contraindicated or inconvenient. Thanks to its liquid form, the drug is absorbed in the stomach and acts faster.

• Children under 6 years old should be given 1 tsp. 2-3 times a day, you can dilute the medicine in 1 tbsp. l. ordinary water;
• children under 12 years old: 1–2 tbsp. l. three times a day, depending on the intensity of the cough;
• teenagers and adults: 1.5–2 tbsp. l. syrup three times a day.

The presence of food in the stomach does not affect the therapeutic effect, but in order for the syrup to act faster, it is undesirable to combine its intake with an alkaline drink. Bromhexine in the drug improves the penetration of antibiotics into tissues, making their therapy more effective.

During the treatment period, it is necessary to drink as much liquid as possible: tea with lemon, berry fruit drinks, fruit juices, water.

Combined drug Ascoril in the treatment of cough and bronchial obstruction

• bronchodilator (by acting on β2 receptors of bronchial smooth muscle); • antiallergic (suppresses the release of histamine induced by exposure to an allergen, since it stabilizes mast cell membranes to some extent); • affects the function of the bronchial epithelium and improves mucociliary clearance (activates the function of the ciliated epithelium, increasing the movement of cilia, which improves mucociliary transport); • reduces the synthesis of leukotrienes; • reduces capillary permeability. The effect of β2-agonists on mucociliary clearance should be especially emphasized: stimulation of β2-receptors present in mucosecreting cells occurs, which leads to an increase in bronchial secretion and improved evacuation. So, salbutamol relaxes the smooth muscles of the bronchi and blood vessels, prevents the development of bronchospasm caused by the effects of histamine, methacholine, cold air and allergens. The drug also inhibits the release of inflammatory mediators from mast cells. In addition, salbutamol enhances mucociliary transport. An equally important component of the drug Ascoril is bromhexine hydrochloride, a mucolytic agent that has an expectorant and antitussive effect. Bromhexine with its active metabolite ambroxol is a mucolytic drug in its pharmacological action. Its mucolytic effect is associated with the depolymerization of mucoprotein and mucopolysaccharide fibers. By increasing the serous component of bronchial secretions, the drug activates the cilia of the ciliated epithelium, reduces the viscosity of sputum, increases its volume and improves discharge. By stimulating the serous cells of the glands of the bronchial mucosa, bromhexine normalizes the ratio of the serous and mucous components of sputum, stimulates the production of enzymes that break down the bonds between mucopolysaccharides of sputum, the formation of surfactant, which also normalizes the rheological parameters of sputum, reducing its viscosity and adhesive properties. Ambroxol (the main metabolite of bromhexine) directly stimulates the movement of cilia and prevents their adhesion, promoting the evacuation of sputum. Bromhexine also has a slight antitussive effect, which is of great importance in the treatment of a number of pathologies where it is undesirable to stimulate the cough reflex. The unique properties of bromhexine are stimulation of the synthesis of endogenous surfactant and improvement of the penetration of the antibiotic into the lung tissue. Such unique qualities of bromhexine often make it the drug of choice for the treatment of pneumonia and brochiectasis. The third active component of Ascoril is guaifenesin, a unique substance that combines mucolytic and reflex effects. It irritates the stomach receptors and thereby stimulates the gastropulmonary reflex, thereby increasing the secretion of the bronchial glands and the activity of the cilia of the ciliated epithelium. Another property of guaifenesin is its ability to reduce the surface tension of the structures of the bronchopulmonary apparatus and stimulate secretory cells of the bronchial mucosa that produce neutral polysaccharides. Guaifenesin depolymerizes acidic mucopolysaccharides, reducing the viscosity of sputum. This multicomponent mechanism of action of guaifenesin facilitates the removal of sputum and promotes the transition of a nonproductive cough to a productive one. So, guaifenesin stimulates the secretion of the liquid part of bronchial mucus, reduces the surface tension and adhesive properties of sputum. An important additional effect of guaifenesin is its mild sedative effect. Guaifenesin reduces anxiety and psychogenic autonomic symptoms. The fourth component of Ascoril syrup is racementol (menthol), a local irritant that gently stimulates the secretion of the bronchial glands, has antiseptic properties, and restores the function of the ciliated epithelium of the bronchial mucosa. It has a coronary dilating, reflex, venotonic, antianginal, analgesic and anti-inflammatory local effect. The effect is mainly due to reflex reactions associated with irritation of sensitive receptors of the mucous membranes, and stimulation of the formation and release of endogenous biologically active substances (enkephalins, endorphins, peptides, kinins) involved in the regulation of pain, vascular permeability and other processes, which provides pain relief and distracting action. Antimicrobial activity is manifested by indiscriminate damage to microbial cells. The irritating (distracting) effect helps reduce pain. Thus, Ascoril is a drug containing a unique combination of substances that simultaneously have a bronchodilator, expectorant and mucolytic effect. Let's consider the area of ​​clinical application of the drug Ascoril. It is most often used for acute and chronic lung diseases accompanied by broncho-obstructive syndrome (BOS). The main manifestations of BOS are shortness of breath, suffocation, a feeling of chest congestion and cough. Differential diagnosis of BOS is a complex medical task. The most common manifestations of biofeedback occur in asthma, COPD and CB. But it should be noted that BOS is often observed in ARVI, acute bronchitis, pneumonia, tuberculosis, post-tuberculosis pneumosclerosis and other acute diseases of the respiratory system. BOS is based on various pathogenetic mechanisms, which can be divided into reversible (inflammation, edema, bronchospasm, mucociliary insufficiency, hypersecretion of viscous mucus) and irreversible (expiratory collapse of small bronchi - “air trap” in pulmonary emphysema, COPD, bronchiolitis), congenital or acquired tracheobronchial pathology (dyskinesia of the membranous part of the trachea and main bronchi), bronchial remodeling, etc. Manifestations of both acute and chronic biofeedback are the same, they intensify with physical activity. The need to prescribe bronchodilators arises in patients suffering from acute and chronic respiratory diseases accompanied by biofeedback. Ascoril for biofeedback in children Most often, bronchial obstruction occurs during acute respiratory viral infections (ARVI). Age-related characteristics play a certain role (in children of the first three years of life): • narrowness of the bronchi and the entire respiratory apparatus, which significantly increases aerodynamic resistance (according to Poiseuille’s rule, the resistance of the airways is inversely proportional to their radius to the 4th power); • pliability of bronchial tract cartilage; • insufficient rigidity of the bone structure of the chest, which freely reacts by retracting compliant places to increase resistance in the airways; • features of the position and structure of the diaphragm; • features of the bronchial wall: a large number of goblet cells that secrete mucus; • rapid reaction of the mucous membrane of the trachea and bronchi - swelling and hypersecretion of mucus in response to the development of a viral infection; • increased viscosity of bronchial secretions associated with high levels of sialic acid; • imperfection of immunological mechanisms: the formation of interferon in the upper respiratory tract, serum immunoglobulin A, secretory immunoglobulin A, and the functional activity of the T-immune system are significantly reduced. Functional disorders of the respiratory system in a small child are also influenced by factors such as longer sleep, frequent crying, and a predominant position lying on the back in the first months of life. In addition, the occurrence of obstruction in childhood can be caused by: • maternal smoking, which has a direct effect on the caliber of the airways developing in the fetus, which affects the lungs (especially by reducing the development of alveoli) in the postnatal period. Maternal smoking leads to a decrease in IL-4 and INF-γ in cord blood and increases the sensitivity of cord blood mononuclear cells to house dust. Other studies of cord blood cells show that maternal smoking leads to an increase in IL-13 and a decrease in the INF-γ mRNA response after stimulation, as well as TNF-α production; • Maternal atopy is also associated with decreased pulmonary function in the newborn, although the exact mechanism is not yet known. Epidemiological studies show that maternal smoking and atopy are also associated with subsequent bronchiolitis in children in the first year of life. Cord blood IL-12 and sCD30 are lower in children who develop bronchiolitis, which may be due to bronchial obstruction preceding bronchiolitis. Thus, maternal smoking has a major impact on the immune response in newborns and on the anatomical features of their lungs. • Infants of mothers with preeclampsia and hypertension and diabetes are at increased risk of transient early obstruction, persistent obstruction, and later obstruction. • Prescription of antibiotics during labor is associated with both early transient obstruction and persistent obstruction. • Respiratory viral infections in early life may be a significantly more important risk factor for bronchial obstruction than atopy. • Severe adenovirus infection can lead to long-term bronchial obstruction in a previously healthy child. Respiratory viruses damage the ciliated epithelium of the mucous membrane of the respiratory tract, increase its permeability to allergens, toxic substances and the sensitivity of the receptors of the submucosal layer of the bronchi, which causes an increase in bronchial hyperreactivity and the occurrence of obstructive manifestations in children. The bronchial epithelium can respond to signals from immune cells that are involved in the initiation and maturation of the innate and adaptive immune response, including structural changes in the airways and angiogenesis. Taking into account the variety of clinical symptoms and their severity, when treating children with ARVI accompanied by biofeedback, it is necessary to influence various components of the pathological process. Modern trends include the use of combined drugs with multidirectional but complementary effects. In young children with severe and moderate obstruction, inhaled use of a combination of a bronchodilator and a mucolytic is effective. Complex treatment of children with respiratory diseases, especially with chronic recurrent inflammatory diseases of the lungs, along with other pathogenetic therapy, includes drugs that help increase the lumen of the bronchi, reduce the viscosity and elasticity of sputum. According to N.A. Geppe et al., the use of Ascoril expectorant in children aged 2 to 10 years with mild or moderate acute respiratory viral infection has a pronounced positive effect on the course of the disease, as assessed by doctors, as well as according to the results of a parent survey. The study included children with acute respiratory diseases that occurred with cough due to the involvement of various parts of the respiratory tract in the inflammatory process (laryngitis, pharyngitis, tracheitis, bronchitis). For children under 6 years of age, Ascoril expectorant was prescribed 5 ml (1 teaspoon) 3 times a day, from 6 to 10 years - 5–10 ml (1–2 teaspoons) 3 times a day. The duration of treatment was 7–10 days, depending on the dynamics of the patients’ condition. In children over 6 years of age, external respiratory function was assessed according to spirography (FVC, FEV1, PEF, minimum volumetric flow rate at the level of 25, 50, 75% VC). All children, including young children, underwent bronchophonography to study the function of external respiration. In children who received the combined drug (Ascoril), compared with the control group of children who received only the mucolytic (bromhexine), faster positive dynamics were observed. In children receiving Ascoril expectorant, the disappearance of cough symptoms was observed 3–4 days earlier than in patients in the comparison group (p<0.05). It is important that the symptoms of night cough disappear 1–2 days faster. A decrease in the severity of cough symptoms was accompanied by improved sleep, increased activity in children, and an improvement in their emotional state. The total score of clinical symptoms during treatment showed a faster effect of Ascoril expectorant compared to the comparison group. The positive dynamics of clinical symptoms was accompanied by a significant improvement in bronchophonography and spirography indicators, indicating normalization of bronchial patency. Tolerability of Ascoril was good in all age groups. One child had an allergic reaction to the drug in the form of a rash. No side effects or adverse reactions were noted in the remaining children. 4% of children receiving the combination drug and 10% of children receiving only the mucolytic (p<0.05), due to insufficient effectiveness of treatment, antibacterial therapy was added. It should be remembered that repeated phenomena of biofeedback during acute respiratory viral infections in childhood require a comprehensive clinical examination of the child to exclude diseases accompanied by biofeedback, and especially asthma. Ascoril in adults, in patients with chronic disease and a history of smoking According to studies conducted on the effectiveness and safety of Ascoril expectorant in patients with various respiratory diseases (ARVI, acute and chronic disease, asthma, COPD, pneumonia) in Russia and abroad, high effectiveness was noted drug (78–96%). This effect is especially clearly seen in patients with chronic broncho-obstructive diseases, for example, against the background of an exacerbation of ARVI [21], which is expressed by a significant improvement in bronchial patency [21], a decrease in the intensity of cough, and easier expectoration of sputum. The onset of action of the drug was registered by the end of the 1st day of administration. ARVI in patients with chronic disease and smokers is quite severe and is accompanied by severe obstruction. In contrast to the course of ARVI in practically healthy individuals, in this case doctors note the development of a productive cough. It should be emphasized that smokers suffer from infectious diseases (including ARVI) much more often than non-smokers. This is largely due to significant disturbances in mucociliary clearance under the influence of tobacco smoking. Tobacco smoke contains a significant amount of free radicals, which, when inhaled into the respiratory tract, upset the balance in the oxidant-antioxidant system. In the process of the formation of this imbalance, which is characterized as oxidative stress, damage occurs to the biological membranes of cells included in the structure of the lung tissue. Acute damage to lung tissue during chronic smoking is transformed into a chronic inflammatory process. Symptomatic treatment of ARVI should be aimed at reducing fever, manifestations of biofeedback, and improving sputum discharge. Overproduction of viscous bronchial mucus requires the use of mucolytic drugs, and bronchial obstruction requires bronchodilator drugs. Therefore, it is desirable to use combination drugs, the action of which is aimed at the main links in the pathogenesis of acute cough during ARVI in smokers. In this regard, the drug Ascoril is of some interest. Its components can reduce cough and symptoms of biofeedback, because all components of the drug have a synergistic effect, improving mucociliary clearance, regulating the secretion of bronchial mucus and its rheological properties, reducing excess bronchial tone. As a result, rapid cleansing of the bronchi from altered bronchial secretions and reduction/cessation of cough occur. Conclusion The combined drug Ascoril expectorant is an effective and safe treatment for acute respiratory diseases occurring with symptoms of bronchial obstruction in children and adults. The results of the studies demonstrated the effectiveness and safety of the use of the drug Ascoril for ARVI with symptoms of biofeedback in adults. Taking Ascoril in the first days of acute respiratory infection reduces the duration of the disease, manifestations of bronchial obstruction, bronchial hyperreactivity, and promotes faster clinical recovery. The work of Russian pediatricians also showed that when treated with Ascoril, its effectiveness was good and high in 96% of cases. These studies showed that Ascoril is a safe drug for the treatment of ARVI in long-term and frequently ill children. Thus, the administration of Ascoril expectorant in children shortens the duration of respiratory viral diseases, reduces the manifestations of bronchial obstruction, and promotes faster clinical recovery. But the most important thing: if children and adults have BOS, they should be thoroughly examined to make a diagnosis. An important aspect of the use of the drug is its good tolerance. It is extremely rare in some patients that tremor and heartbeat are noted, which pass immediately after the cancellation of the drug or reduction of the dose. These side effects are primarily due to the ascoril syrup with Salbutamol, which has high absorption during oral administration. In this regard, ascoril should be assigned with caution to patients taking methylxanthines, monoaminexidase inhibitors and tricyclic antidepressants (the likelihood of tachyarrhythmia, falling blood pressure). It is not recommended to be taken simultaneously with non-election β-blockers. The use of the drug in adults also has high effectiveness. When using the drug Ascoril in elderly people, as well as in patients with concomitant cardiovascular diseases, you should remember the side effects of salbutamol. Literature 1. Belevsky A.S. The possibility of optimizing the treatment of acute bronchitis on the background of SARS // attending physician. 2001. No. 8. P. 58. 2. Geppe N.A., Seliverstova N.A., Malyshev V.S., Utyusheva M.G., Starostina L.S., Ozerskaya I.V. Bronchophonographic examination of lungs in patients with bronchial asthma early age // Pulmonology. 2008. No. 3. S. 38-41. 3. Geppe N.A., Sneygnotskaya M.N. The place of mucopot controls in the treatment of bronchopulmonary diseases in children // Pharmacle. 2004. No. 17. S. 35–39. 4. Geppe N.A., Seliverstova N.A., Malyshev V.S., Mashukova N.G., Kolosova N.G. The causes of bronchial obstruction in children and the direction of therapy // RMG, 2011. No. 22. 5. Zaitseva O.V. Mucolytics in the treatment of respiratory diseases in children // Consilium Provisorum. 2005. No. 1. P. 24-26. 6. Klyachkina I.L. Treatment of coughing for SARS and influenza // breast cancer. 2012. No. 1. S. 1–7. 7. Klyachkina I.L. Treatment of cough with acute respiratory infection and influenza in risk groups // Pharmacle. 2010. No. 5. S. 125-132. 8. Klyachkina I.L., Dmitriev Yu.K. Treatment of mild exacerbations of chronic obstructive lung disease // Clinical medicine. 2012. No. 3. S. 79–82. 9. Sokolova L.V., Mosorsnitsky Yu.L., Sorokina E.V., Gryazina O.V. The use of the drug ascoril in children with respiratory diseases // Issues of modern pediatrics. 2002. No. 1. P. 45. 10. Chuchalin A.G. Tobacco -smoking and respiratory systems // BMJ. 2008. T. 16. No. 22. S. 1477–1482. 11. Chuchalin A.G., Abrosimov V.N. Cough. Ryazan, 2000. 12. Fedoseev G.B., Zinakova M.K., Rodkina E.I. Schukina T.V. Clinical aspects of the use of ascoril in a pulmonological clinic // New St. Petersburg medical statements. 2002. No. 2 (20). S. 64–67. 13. Fedoseev G.B., Orlova N.Yu., Shalyuga L.V. The use of Askil in outpatient practice // New St. Petersburg medical statements. 2002. No. 1 (19). pp. 69–70. 14. Ainapure SS, Desai A., Korde K. Efficacy and Safety of ascoril in the Management of Couth - National Study Group Report // J Indian Med Assoc. 2001 Feb. Vol. 99 (2). P.111, 114. 15. β2-agonists. From Pharmacological Properties to EVERYDAY CLINICAL PRACTICE: International Workshop Report. London, 2000. 16. Garau J. who do we need to eradicate patio in respiratory tract infection? // Int j infect dis. 2003. Vol. 7 (1). R. 5-12. 17. Dicpinigaitis PV, Gayle Ye Sensitivity Effect of Guaifenesin on Couth Reflex // Chest. 2003. Vol. 124. R. 2178-2181. 18. Jackson DJ, Gangnon Re, Evans Md et al. Wheezing Rhinovirus Illnesses in Early Life Predict Asthma Development in High -Risk Children // Am J Respir Crit Care Med. 2008. Vol. 178. R. 667–672. 19. Jayaram S., Desi A. Efficacy and Safety of ascoril Expectorant and Other Couth Formula in the Treatment of Couth Management in Paediatric and Adults - - a randomised dup Le - Blind Comparative Trial // J Indian Med Assoc. 2000 FEB. Vol. 98 (2). R. 68–70. 20. KIMYA Y., kucukkkomurcu S., Ozan H., Uncu G. Antenatal Ambroxol Usage in the Prevention of Infant Respiratry Distress Syndrome. Beneficial and Adverse Effects // Clin Exp Obstet Gynecol. 1995. Vol. 22. R. 204–211. 21. Kotaniemi - sorja¨nen a, vainionpa¨a¨ r, reijonen tm, et al. Rhinovirus --induced Wheezing in infancy - the first sign of childhouse asthma? // J allergy Clin Immunol. 2003. Vol. 111. R. 66–71. 22. Martinez FD Inhaled Corticosteroids and Asthma Prevention // Lancet. 2006. Vol. 368. R. 708-710. 23. Midulla F., Scagnlari C., Bonci E., et al. Respiratory Syncytial Virus, Human Bocavirus and Rhinovirus Bronchiolites in Infants // Arch Dis Child. 2010. Vol. 95. R. 35–41. 24. Pala P., bjarnason R., Sigurbergsson F. et al. Enhanced IL -4 Responses in Children with a History of Respiratory Syncytial Virus Bronchiolitis in infancy // EUR Respir J. 2002. Vol. 20. R. 376–382. 25. Prabhu Shankar S., Chandrashhekharan S., Bolmall CS, Baliga V. Efficacy, Safety and Tolerability of Salbutamol + Guaipheenesin + Bromhexine (ascoril) Expectorant Versus Expectoral S Containing Salbutamol and Either Guaipheenesin or Bromhexine in Productive Couth: A Randomid Controlled Comparative Study // J Indian Med Assoc. 2010 may. Vol. 108 (5). R. 313–320. 26. Rahman I., AdCock IM. Oxidate Stress and Redox Regulation of Lung InflamMation in Copd // EUR Respir J. 2006. Vol. 28. R. 219–242. 3 1973. Vol. 28. R. 742. 28. Simpson A., Maniatis M., Jury F. et al. Polymorphisms in a Disintegrin and Metalloproteinase 33 (Adam33) Predict Impaired Early Lung Function // Am Rev Respir Crit Care Med. 2005. Vol. 172. R. 55–60. 29. Smyth RL, Fletcher Jn, Thomas Hm et al. Respiratory Syncytial Virus and Wheeze // Lancet. 1999. Vol. 354. R. 1997–1998. 30. Wauer RR, SCHMALISCH G., Bohme B., Arand J., Lehmann D. RANDOMIZED DOUBLE BLIND TRIALO of AMBROXOL FOR THE TREATMENTRY DISPIRATORY DISTRESS SYNDROME // EUR J PEDIATR. 1992. Vol. 151. R. 357–363.

Side effects

Ascoril rarely causes adverse reactions in the body and is well tolerated by children and adults. In some cases it is possible:

• impaired taste, dry mouth;
• loss of appetite, nausea;
• cramps in the stomach;
• tremor;
• increased drowsiness;
• nervous excitability;
• headache.

In isolated cases, there is a change in the color of urine - pink. In case of allergic reactions to the drug, urticaria, skin itching, red spots, and swelling of the mucous membranes may appear.

Contraindications

It is necessary to stop using the drug:

• with exacerbations of gastritis and peptic ulcer;
• with stomach or intestinal bleeding;
• insulin-dependent diabetes mellitus;
• thyrotoxicosis;
• glaucoma;
• myocarditis;
• severe stage of urolithiasis;
• liver or kidney failure.

The product is also prohibited for pregnant and lactating women, as it penetrates into all tissues of the body and breast milk. Ascoril tablets are contraindicated in children under 6 years of age. Syrup - for infants and children up to 2 years old.